1626387-81-2 Usage
Description
(R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt is a complex organic compound characterized by a quinazoline ring with a 7-methoxy and 3-chloro-2-fluorophenyl substitution, along with a 2,4-dimethylpiperazine-1-carboxylate group. (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt is presented as a hydrochloride salt, which may enhance its solubility and stability. Its intricate structure, featuring multiple functional groups, suggests a wide range of potential applications, particularly in the pharmaceutical industry, due to the known biological activities of quinazoline derivatives.
Uses
Used in Pharmaceutical Industry:
(R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt is used as a potential pharmaceutical agent for its diverse biological activities. The quinazoline core is known for its antitumor and antimicrobial properties, making it a candidate for the development of new drugs targeting various diseases.
Used in Drug Development for Antitumor Agents:
In the field of oncology, this compound is used as a precursor or building block in the synthesis of antineoplastic drugs. Its structure allows for potential interactions with cellular targets, such as enzymes or receptors, that are implicated in tumor growth and progression.
Used in Drug Development for Antimicrobial Agents:
(R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt is also utilized in the development of antimicrobial drugs, given the broad-spectrum activity often associated with quinazoline derivatives. This makes it a candidate for treating infections caused by bacteria and other microorganisms.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt serves as a valuable research tool. It can be used to study structure-activity relationships, optimize drug candidates, and understand the mechanisms of action of quinazoline-based drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 1626387-81-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,6,3,8 and 7 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1626387-81:
(9*1)+(8*6)+(7*2)+(6*6)+(5*3)+(4*8)+(3*7)+(2*8)+(1*1)=192
192 % 10 = 2
So 1626387-81-2 is a valid CAS Registry Number.
1626387-81-2Relevant articles and documents
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Zeng, Qingbei,Wang, Jiabing,Cheng, Ziqiang,Chen, Kan,Johnstr?m, Peter,Varn?s, Katarina,Li, David Yunzhi,Yang, Zhen Fan,Zhang, Xiaolin
, p. 8200 - 8215 (2015)
Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain metastases and leptomeningeal metastases. These patients have poor prognosis as there are no approved drugs for these indications. Available agents have poor efficacy for these patients even at well above their standard dose. Herein, we report the discovery of (4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate 1m (AZD3759), an investigational drug currently in Phase 1 clinical trial, which has excellent central nervous system penetration and which induces profound regression of brain metastases in a mouse model.
Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor
-
, (2014/09/29)
The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
